New drugs in the palliative chemotherapy of advanced non-small-cell lung cancer

Onkologie

Volumn 24, Issue 5, 2001, Pages 416-421

  Malayeri, R ^a   Pirker, R ^a   Huber, H ^a  

^a Abteilung fur Innere Medizin I   (Austria)

Author keywords

Elderly patients; New drugs; Non small cell lung cancer (NSCLC); Palliative chemotherapy; Second line chemotherapy

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; NAVELBINE; NEW DRUG; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; TENIPOSIDE; TIRAPAZAMINE; VINDESINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG SCREENING; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034755993     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055121     Document Type: Review

References (63)

1. Regional lymph node classification for lung cancer staging
2. Combined modality therapy in NSCLC
3. Adjuvant and induction chemotherapy in non-small cell lung cancer
4. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer
5. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
6. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer
7. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer
8. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
9. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
10. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
11. Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial
12. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer
13. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group
14. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study
15. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study
16. Phase II trial of gemcitabine in advanced non-small-cell lung cancer
17. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
18. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
19. Combined cisplatin and gemcitabine for non-small cell lung cancer: Influence of scheduling on toxicity and drug delivery
20. Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer
21. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer
22. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer
23. Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion
24. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer
25. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC)
26. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
27. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
28. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
29. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin
30. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer
31. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer
32. A Randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small-cell lung cancer. A preliminary analysis
33. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study
34. A phase II trial of docetaxel in advanced non-small cell lung cancer
35. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer
36. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer
37. Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG)
38. Docetaxel as a single agent in first-line therapy of non-small cell lung cancer
39. Docetaxel (Taxotere) plus cisplatin: An active and well-tolerated combination in patients with advanced non-small cell lung cancer
40. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
41. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
42. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer
43. Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
44. Treatment of patients with advanced non-small cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor
45. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer
46. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
47. The role of irinotecan in non-small-cell and small-cell lung cancer
48. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
49. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
50. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIM-TA) and cisplatin: A multicenter phase II trial
51. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
52. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
53. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
54. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
55. Longterm analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer
56. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
57. Gemcitabine + vinorelbine (GV) yields better survival than vinorelbine (V) alone in elderly non-small cell lung cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Group (SICOG) phase III trial
58. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study
59. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
60. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer: A Southwest Oncology Group (SWOG) trial
61. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer
62. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
63. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer